1. Defining the Expectations of Your Center’s Leaders Cancer Center Administrators’ Forum April 2011

2. Cancer Center Leadership Roles  Cancer Center Director: this role is usually well defined both by the NCI CCSG guidelines and by the institution ­ Vision/strategic planning- Budget ­ Recruitment- Fundraising ­ Equivalent to departmental chair- Space  Deputy Director, Associate Directors, Program Leaders and Shared Resource Directors ­ Often times the authority, expectations and responsibilities of these positions are ill defined

3. Today’s Presentations  Associate Director Role ­ Anita Harrison, Hollings Cancer Center, MUSC ­ Melanie Thomas, Associate Director of Clinical Investigations  Program Leader Role ­ Kimberly Kerstann, Winship Cancer Institute, Emory ­ Paula Vertino, Cancer Genetics & Epigenetics Program Leader  Shared Resource Director Role ­ Stephen Long, Greenebaum Cancer Center, U of Maryland ­ Nicholas Ambulos, Director of Shared Services

4. Associate Director  Common Cancer Center Associate Director Positions ­ Basic Science- Prevention & Control ­ Clinical Investigations- Cancer Disparities ­ Translational Research- Administration ­ Shared Resources- Clinical Affairs ­ Education  Generally, these positions are considered the Center’s “Senior Leadership” and report to the Director or Deputy Director  Typically, they receive CCSG support for 10-20% effort; total Center support can be up to 50%  Meet 1-2 times a month as a group with Director/Deputy

5. Associate Directors  Formulate priorities, strategies and provide input into the allocation of resources  Closely monitor the strength of several of the CCSG Essential Characteristics (cancer focus, research facilities, inter/transdisciplinary interactions, organizational capabilities) across the Center  Evaluate Center’s progress in meeting strategic planning goals  Expected to be inter-connected with other departmental/college/campus-wide efforts to build synergy with the Cancer Center

6. Defining the Associate Director’s Role  Create a job description for each  Role should be distinct from other roles but clarify any areas of overlap and make sure that these are well articulated ­ Associate Director (Breadth) vs Program Leader (Depth)  Define what financial resources they have to accomplish their job and/or what part of the Center’s budget are they accountable for  Effectiveness should be annually reviewed (peer review by other Associate Directors and Program Leaders; EAB)

7. Associate Director of Clinical Investigations Melanie B. Thomas, MD Associate Professor of Medicine Grace E. DeWolff Chair in GI Oncology  Recruited in 2008 from University of Texas M.D. Anderson Cancer Center  Nationally-recognized for her multidisciplinary clinical research program in hepatobiliary cancer  2009 NCI Clinical Leadership Team Award  Cancer Center supports 30% effort for this role

8. Authorities and Responsibilities

9.  Identify clinical research expertise needed and work with Director and institutional leaders (dept, divisions) to facilitate faculty recruitment  Integrate investigators into multidisciplinary groups in which they are actively engaged with basic and population based researchers in developing translational research

10. Cancer Genes & Molecular Regulation Lipid Signaling in Cancer Developmental Cancer Therapeutics Cancer Immunology HCC Research Programs Clinical and Laboratory Interface TRANSLATIONAL RESEARCH H&N GU Breast Thoracic Established Disease-based Research Groups with Key Clinical Faculty Hem/ Mal Baker Jenrette Kramer Christiansen Day Gillespie Shirai Sharma Reed Denlinger Silvestri Simon Kraft Drabkin Keane Golshayan Stuart Kraveka Hudspeth Costa Neuro Giglio Patel GI Thomas Esnaola Chin Camp Cancer Prevention & Control

11. Authorities and Responsibilities  Promotion of investigator initiated trials, especially with Center’s pre-clinical investigators  Develop consortium relationships with NCI Phase I and Phase II awardees as well as industry partners to develop and conduct novel trials  Promotion and facilitation of the development of leadership within cooperative groups  Increase clinical trial accrual; work with Associate Director of Cancer Disparities to promote minority participation

12. Strategies Employed  ExPERT – junior clinical investigators meet monthly with Dr. Thomas and invited shared resource directors and program leaders to discuss correlative science concepts  Pfizer 3D Program (Sept 2010)  Disease & Program Retreats 10 in 2010  Abney Clinical Scholars – HCC salary support for new junior faculty for protected time (Graybill, Young)  Ongoing faculty recruitment – 2010  HCC further investing in CTO to support accrual/protocol development (VA, East Cooper, Phase I)

13. Shifting the Portfolio Toward IITs HCC Active Therapeutic Studies by Sponsor 2008 (N=122) 2011 (N=126) 2 Active Phase I Trials in 200810 Active Phase I Trials in 2011

14. 15 by 2015 The Next Breakthrough Could Be Yours Less than 1% of adults in SC diagnosed with cancer enroll on a therapeutic clinical trial 254 patients (12.4% of new patients) enrolled onto a therapy trial at the HCC in 2010 HCC led statewide public policy changes in 2010 to ensure every person with insurance has access to cancer clinical trials The HCC goal is to increase enrollment to therapy trials to 15% by 2015

15. Goals: - Raise everyone's awareness of clinical trials - Integrate clinical trials into all standard pt care practices - Foster culture that values and promotes faculty/staff involvement in clinical trials Strategies: - Continual rounding with faculty/staff about clinical trials - Identify and knock down ALL barriers to enrolling - Visuals: banners (12), posters (80), buttons, info cards - Commitment by MUSC leadership to hold faculty/staff accountable for growth in clinical trials 15 by 2015 The Next Breakthrough Could Be Yours

16. HCC Therapeutic Accrual to Cancer Clinical Trials (assumes a 3% growth in overall pt volume/year)